Trend
—
Key levels
—
Latest news & SEC filings
No headlines in the last 90 days.
· Healthcare
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for DVAX.
Start Free Trial →Valuation Verdict
INSUFFICIENT DATA
Methods Used
N/A
Fair Value
$N/A
19
Moat Score
NONE
6/9
Piotroski Score
2.4
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
NEUTRAL
Short Squeeze Risk
LOW
Signal: NEUTRAL
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
19.4%
3yr Revenue CAGR
-14.2%
EPS Growth YoY
500%
FCF Growth YoY
-37.6%
Revenue Trend
STABLE
SEPT's Trading AI has generated a free, downloadable PDF research report for DYNAVAX TECHNOLOGIES CORP (DVAX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (0 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →DYNAVAX TECHNOLOGIES CORP (DVAX) is at $15.50, up 0.00% (+$0.00) at the Feb 9, 2026 close.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.